FDA 483 - Lilly del Caribe, Inc - February 25, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Lilly del Caribe, Inc. in Carolina, PR, a drug product manufacturer, revealed significant deficiencies in quality control laboratory practices. The firm failed to adequately investigate out-of-specification results, often invalidating them without confirmed root causes or extending investigations to other affected batches. Additionally, laboratory controls allowed for the manipulation of test parameters and recalculation of OOS results stemming from incorrect sample preparation, compromising data integrity.
ID · 46c27262-2d1c-43db-8d65-648ca4b97af0